{"id":512870,"date":"2021-07-14T08:05:34","date_gmt":"2021-07-14T12:05:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/"},"modified":"2021-07-14T08:05:34","modified_gmt":"2021-07-14T12:05:34","slug":"early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/","title":{"rendered":"Early Look at Second Quarter Metrics for Phexxi\u00ae Reveals Strong Growth"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">&#8211; High Percentage of Women Converting to Phexxi from Hormonal Birth Control &#8211;<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">SAN DIEGO<\/span>, <span class=\"xn-chron\">July 14, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0Evofem Biosciences, Inc., (NASDAQ: EVFM) today provided a preliminary look at Phexxi<sup>\u00ae<\/sup> (lactic acid, citric acid and potassium bitartrate) data for the second quarter of 2021 and revealed new insights into the demographics of women who are using this hormone-free contraceptive method.\u00a0\u00a0\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/780907\/Evofem_Logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/780907\/Evofem_Logo.jpg\" title=\"(PRNewsfoto\/Evofem Biosciences, Inc.)\" alt=\"(PRNewsfoto\/Evofem Biosciences, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<ul type=\"disc\">\n<li>More than 14,000 Phexxi units were dispensed in the second quarter of 2021. <\/li>\n<li>Over 5,400 healthcare providers prescribed Phexxi in the second quarter of 2021. <\/li>\n<li>Over 7,000 healthcare providers have prescribed Phexxi since launch. <\/li>\n<li>60% of new Phexxi users are between the ages of 18 to 34 years. <\/li>\n<li>For more than 50% of women converting to Phexxi, their last prior contraceptive used was hormonal. <\/li>\n<\/ul>\n<p>&#8220;The volume of women switching from hormonal birth control to Phexxi indicates a movement is happening,&#8221; said\u00a0Saundra Pelletier, Chief Executive Officer of Evofem Biosciences. &#8220;Women are seeking a healthy lifestyle and choosing Phexxi for hormone-free contraception is a natural fit.&#8221; <\/p>\n<p>The Company will discuss Phexxi trends and other key metrics in detail on its second quarter earnings call in August. Call details and access information will be announced in late July.<\/p>\n<p>\n        <b>About Evofem Biosciences<br \/><\/b>Evofem Biosciences, Inc., (NASDAQ:\u00a0EVFM) is developing and commercializing innovative\u00a0products to address unmet needs in women&#8217;s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company launched its first FDA-approved commercial product,\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3227718-1&amp;h=1433910822&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3181101-1%26h%3D2423476810%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3171899-1%2526h%253D778655112%2526u%253Dhttps%25253A%25252F%25252Fwww.phexxi.com%25252F%2526a%253DPhexxi%2525C2%2525AE%26a%3DPhexxi%25C2%25AE&amp;a=Phexxi%C2%AE\" rel=\"nofollow noopener\">Phexxi<sup>\u00ae<\/sup><\/a>\u00a0(lactic acid, citric acid and potassium bitartrate), in\u00a0the United States\u00a0in\u00a0September 2020. The Company is evaluating lead product candidate EVO100 for the prevention of urogenital\u00a0<i>Chlamydia trachomatis<\/i>\u00a0and\u00a0<i>Neisseria gonorrhoeae\u00a0<\/i>infection in women in the ongoing Phase 3 clinical trial,\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3227718-1&amp;h=2538329732&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3181101-1%26h%3D2744333749%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3171899-1%2526h%253D4049316790%2526u%253Dhttps%25253A%25252F%25252Fwww.evoguardstudy.com%25252Fct%25252F%2526a%253D%252527EVOGUARD%26a%3D%2527EVOGUARD&amp;a=%27EVOGUARD\" rel=\"nofollow noopener\">&#8216;EVOGUARD<\/a>.&#8217; For more information, please visit\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3227718-1&amp;h=2870295084&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3181101-1%26h%3D2441905487%26u%3Dhttp%253A%252F%252Fwww.evofem.com%252F%26a%3Devofem.com&amp;a=evofem.com\" rel=\"nofollow noopener\">evofem.com<\/a>.<\/p>\n<p>\n        <i>Phexxi<sup>\u00ae<\/sup>\u00a0is a registered trademark of Evofem Biosciences.<\/i>\n      <\/p>\n<p>\n        <b>About\u00a0PHEXXI<sup><br \/><\/sup><\/b>Phexxi\u00a0is an on-demand method of birth control used to prevent pregnancy. Phexxi<sup>\u00a0<\/sup>is not effective\u00a0when\u00a0used\u00a0after\u00a0sex. For more information about Phexxi, talk to your healthcare provider and see full\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3227718-1&amp;h=2251679587&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3144422-1%26h%3D2595296307%26u%3Dhttps%253A%252F%252Fwww.phexxi.com%252Fthemes%252Fcustom%252FphexxiDTC%252Fdist%252Fpdf%252FPhexxiUSPI.pdf%26a%3DProduct&amp;a=Product\" rel=\"nofollow noopener\">Product<\/a>\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3227718-1&amp;h=2226114963&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3144422-1%26h%3D1766707431%26u%3Dhttps%253A%252F%252Fwww.phexxi.com%252Fthemes%252Fcustom%252FphexxiDTC%252Fdist%252Fpdf%252FPhexxiUSPI.pdf%26a%3DInformation&amp;a=Information\" rel=\"nofollow noopener\">Information<\/a>, which is available at\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3227718-1&amp;h=170021402&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3144422-1%26h%3D2647397128%26u%3Dhttps%253A%252F%252Fwww.phexxi.com%252Fthemes%252Fcustom%252FphexxiDTC%252Fdist%252Fpdf%252FPhexxiUSPI.pdf%26a%3Dhttps%253A%252F%252Fwww.phexxi.com%252Fthemes%252Fcustom%252FphexxiDTC%252Fdist%252Fpdf%252FPhexxiUSPI.pdf&amp;a=https%3A%2F%2Fwww.phexxi.com%2Fthemes%2Fcustom%2FphexxiDTC%2Fdist%2Fpdf%2FPhexxiUSPI.pdf\" rel=\"nofollow noopener\">https:\/\/www.phexxi.com\/themes\/custom\/phexxiDTC\/dist\/pdf\/PhexxiUSPI.pdf<\/a>.<\/p>\n<p>\n        <b>IMPORTANT\u00a0SAFETY\u00a0INFORMATION<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>Rare cases (0.36%) of bladder and kidney infection have been reported. If you have a history of urinary tract problems that keep coming back, you should not use Phexxi. <\/li>\n<li>Contact your healthcare provider if you are experiencing genitourinary side effects such as vaginal burning, itching, discharge, genital discomfort (including in male partners), yeast infection, urinary tract infection or bacterial vaginosis. <\/li>\n<li>Phexxi does not protect against any sexually transmitted infections, including HIV.<\/li>\n<\/ul>\n<p>\n        <b>Please report side effects by contacting Evofem Biosciences\u00a0toll-free at 1-833-EVFMBIO or\u00a0contact\u00a0FDA\u00a0at\u00a01-800-FDA-1088\u00a0<\/b><br \/>\n        <b><br \/>\n          <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3227718-1&amp;h=773834141&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3144422-1%26h%3D3611967282%26u%3Dhttp%253A%252F%252Fwww.fda.gov%252Fmedwatch%26a%3Dor%25C2%25A0www.fda.gov%252Fmedwatch.&amp;a=or%C2%A0www.fda.gov%2Fmedwatch.\" rel=\"nofollow noopener\">or\u00a0www.fda.gov\/medwatch.<\/a><br \/>\n        <\/b>\n      <\/p>\n<p>\n        <b>Forward-Looking Statements<br \/><\/b>This press release includes &#8220;forward-looking statements,&#8221; within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward- looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could impair the value of Evofem Biosciences&#8217; assets and business, are disclosed in the Company&#8217;s SEC filings, including its Annual Report on Form 10-K for the year ended\u00a0December 31, 2020\u00a0filed with the SEC on\u00a0March 4, 2021. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law. <\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prntblns\">\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Investor Relations Contact<\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Amy Raskopf<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"mailto:araskopf@evofem.com\" class=\"prnews_a\" rel=\"nofollow noopener\">araskopf@evofem.com<\/a><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Mobile: (917) 673-5775<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Media Contact<\/b><br \/>\n                  <br \/>Ellen Thomas<br \/><a target=\"_blank\" href=\"mailto:ethomas@evofem.com\" class=\"prnews_a\" rel=\"nofollow noopener\">ethomas@evofem.com<\/a>\u00a0<br \/>Mobile: (718) 490-3248<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA42911&amp;sd=2021-07-14\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth-301333370.html\">https:\/\/www.prnewswire.com\/news-releases\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth-301333370.html<\/a><\/p>\n<p>SOURCE  Evofem Biosciences, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA42911&amp;Transmission_Id=202107140800PR_NEWS_USPR_____LA42911&amp;DateId=20210714\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; High Percentage of Women Converting to Phexxi from Hormonal Birth Control &#8211; PR Newswire SAN DIEGO, July 14, 2021 \/PRNewswire\/ &#8212;\u00a0Evofem Biosciences, Inc., (NASDAQ: EVFM) today provided a preliminary look at Phexxi\u00ae (lactic acid, citric acid and potassium bitartrate) data for the second quarter of 2021 and revealed new insights into the demographics of women who are using this hormone-free contraceptive method.\u00a0\u00a0\u00a0 More than 14,000 Phexxi units were dispensed in the second quarter of 2021. Over 5,400 healthcare providers prescribed Phexxi in the second quarter of 2021. Over 7,000 healthcare providers have prescribed Phexxi since launch. 60% of new Phexxi users are between the ages of 18 to 34 years. For more than 50% of women converting to Phexxi, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Early Look at Second Quarter Metrics for Phexxi\u00ae Reveals Strong Growth&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-512870","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Early Look at Second Quarter Metrics for Phexxi\u00ae Reveals Strong Growth - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Early Look at Second Quarter Metrics for Phexxi\u00ae Reveals Strong Growth - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; High Percentage of Women Converting to Phexxi from Hormonal Birth Control &#8211; PR Newswire SAN DIEGO, July 14, 2021 \/PRNewswire\/ &#8212;\u00a0Evofem Biosciences, Inc., (NASDAQ: EVFM) today provided a preliminary look at Phexxi\u00ae (lactic acid, citric acid and potassium bitartrate) data for the second quarter of 2021 and revealed new insights into the demographics of women who are using this hormone-free contraceptive method.\u00a0\u00a0\u00a0 More than 14,000 Phexxi units were dispensed in the second quarter of 2021. Over 5,400 healthcare providers prescribed Phexxi in the second quarter of 2021. Over 7,000 healthcare providers have prescribed Phexxi since launch. 60% of new Phexxi users are between the ages of 18 to 34 years. For more than 50% of women converting to Phexxi, &hellip; Continue reading &quot;Early Look at Second Quarter Metrics for Phexxi\u00ae Reveals Strong Growth&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-14T12:05:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/780907\/Evofem_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Early Look at Second Quarter Metrics for Phexxi\u00ae Reveals Strong Growth\",\"datePublished\":\"2021-07-14T12:05:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\\\/\"},\"wordCount\":661,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/780907\\\/Evofem_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\\\/\",\"name\":\"Early Look at Second Quarter Metrics for Phexxi\u00ae Reveals Strong Growth - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/780907\\\/Evofem_Logo.jpg\",\"datePublished\":\"2021-07-14T12:05:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/780907\\\/Evofem_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/780907\\\/Evofem_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Early Look at Second Quarter Metrics for Phexxi\u00ae Reveals Strong Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Early Look at Second Quarter Metrics for Phexxi\u00ae Reveals Strong Growth - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/","og_locale":"en_US","og_type":"article","og_title":"Early Look at Second Quarter Metrics for Phexxi\u00ae Reveals Strong Growth - Market Newsdesk","og_description":"&#8211; High Percentage of Women Converting to Phexxi from Hormonal Birth Control &#8211; PR Newswire SAN DIEGO, July 14, 2021 \/PRNewswire\/ &#8212;\u00a0Evofem Biosciences, Inc., (NASDAQ: EVFM) today provided a preliminary look at Phexxi\u00ae (lactic acid, citric acid and potassium bitartrate) data for the second quarter of 2021 and revealed new insights into the demographics of women who are using this hormone-free contraceptive method.\u00a0\u00a0\u00a0 More than 14,000 Phexxi units were dispensed in the second quarter of 2021. Over 5,400 healthcare providers prescribed Phexxi in the second quarter of 2021. Over 7,000 healthcare providers have prescribed Phexxi since launch. 60% of new Phexxi users are between the ages of 18 to 34 years. For more than 50% of women converting to Phexxi, &hellip; Continue reading \"Early Look at Second Quarter Metrics for Phexxi\u00ae Reveals Strong Growth\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-14T12:05:34+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/780907\/Evofem_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Early Look at Second Quarter Metrics for Phexxi\u00ae Reveals Strong Growth","datePublished":"2021-07-14T12:05:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/"},"wordCount":661,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/780907\/Evofem_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/","name":"Early Look at Second Quarter Metrics for Phexxi\u00ae Reveals Strong Growth - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/780907\/Evofem_Logo.jpg","datePublished":"2021-07-14T12:05:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/780907\/Evofem_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/780907\/Evofem_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/early-look-at-second-quarter-metrics-for-phexxi-reveals-strong-growth\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Early Look at Second Quarter Metrics for Phexxi\u00ae Reveals Strong Growth"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/512870","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=512870"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/512870\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=512870"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=512870"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=512870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}